Ascendis Pharma A/S (ASND)
143.01
-1.82
(-1.26%)
USD |
NASDAQ |
Apr 24, 16:00
143.01
0.00 (0.00%)
After-Hours: 18:29
Ascendis Pharma Total Liabilities (Quarterly): 1.074B for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.074B |
| September 30, 2023 | 1.002B |
| June 30, 2023 | 824.82M |
| March 31, 2023 | 871.34M |
| December 31, 2022 | 886.22M |
| September 30, 2022 | 807.81M |
| June 30, 2022 | 751.05M |
| March 31, 2022 | 786.23M |
| December 31, 2021 | 227.90M |
| September 30, 2021 | 245.52M |
| June 30, 2021 | 195.59M |
| March 31, 2021 | 190.49M |
| December 31, 2020 | 173.53M |
| September 30, 2020 | 110.99M |
| June 30, 2020 | 93.87M |
| March 31, 2020 | 80.05M |
| December 31, 2019 | 89.19M |
| September 30, 2019 | 81.00M |
| June 30, 2019 | 104.70M |
| March 31, 2019 | 50.85M |
| Date | Value |
|---|---|
| December 31, 2018 | 44.52M |
| September 30, 2018 | 36.06M |
| June 30, 2018 | 42.36M |
| March 31, 2018 | 21.47M |
| December 31, 2017 | 28.51M |
| September 30, 2017 | 23.43M |
| June 30, 2017 | 18.23M |
| March 31, 2017 | 19.17M |
| December 31, 2016 | 14.23M |
| September 30, 2016 | 13.86M |
| June 30, 2016 | 13.15M |
| March 31, 2016 | 12.20M |
| December 31, 2015 | 12.51M |
| September 30, 2015 | 10.74M |
| June 30, 2015 | 13.89M |
| March 31, 2015 | 13.10M |
| December 31, 2014 | 15.64M |
| September 30, 2014 | 16.79M |
| December 31, 2013 | 28.17M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
80.05M
Minimum
Mar 2020
1.074B
Maximum
Dec 2023
452.42M
Average
227.90M
Median
Dec 2021
Total Liabilities (Quarterly) Benchmarks
| Evaxion Biotech AS | 17.63M |
| Autolus Therapeutics PLC | 263.91M |
| Adaptimmune Therapeutics PLC | 243.10M |
| NuCana PLC | 16.46M |
| TC BioPharm (Holdings) PLC | 7.957M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 912.60M |
| Shareholders Equity (Quarterly) | -161.05M |
| Debt to Equity Ratio | -3.744 |
| Current Ratio | 3.561 |
| Net Debt Paydown Yield | -0.17% |